ReviewAdvances in experimental medicine and biology2025
Immunogenic Switch of RPE Cells.
Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Polyphenol-based self-assembled nanoparticles treating uveitis by inflammation-oxidative stress suppression.Materials today. Bio · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The barrier function of the retinal pigment epithelium (RPE) secures a highly selective exchange of molecules between the blood stream of the choroid and retina but also maintenance of the immune privilege of the retina. The latter function includes a mechanical barrier through the tight junctions and immune barrier of either membrane bound or secreted immune-suppressive factors in response to increasing inflammatory activities in the outer retina. However, in disease, both physical and immune barriers are compromised to allow accumulation of immune cells in the subretinal space or even to pass across the RPE into the retinal space. The ability of the RPE to secrete immune stimulatory factors such as MCP-1, as a response to the increased inflammation, suggests that disease goes along with an immunogenic switch. We recently found that stressed RPE cells express the transcription factor FoxP3 and its activation leads to secretion of pro-inflammatory factors. Indeed, RPE cells in either mouse models with age-related macular degeneration (AMD) relevance or in retinas from AMD patients, express FoxP3 in the RPE, which was not observed in healthy donors. FoxP3 appears first as a rescue factor for the RPE in the increasing presence of pro-inflammatory proteins such as IL1β or active complement that eventually changes the immunogenic phenotype from anti-inflammatory to pro-inflammatory.
Indexed as
Identifiers
39930224What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.